目的:探讨顺尔宁治疗小儿哮喘的临床疗效.方法:将我院2009年5月～2010年6月收治的小儿哮喘患儿100例,随机分为对照组与治疗组,每组50例,对照组给予β<,2>-受体激动剂以及支气管扩张剂等常规治疗;治疗组在常规治疗的基础上给予顺尔宁治疗.两组疗程均为3个月,随访6个月.观察两组治疗前后的血气指标变化和1秒钟用力呼气容积(FEV1);观察症状消失时间、不良反应发生情况及复发率;评定临床疗效.结果:治疗后,治疗组的PaO2(75.1±6.7)mm Hg和PaCO2(33.5±5.1)mm Hg值均明显优于对照组[(70.0±6.2)mm Hg、(39.9±5.6)mm Hg](P<0.05);治疗组的FEV1(90±18)%明显高于对照组(82±15)%(P<0.05);治疗组的咳嗽、气促及哮鸣音等临床症状消失时间[(7.6±4.2)d、(8.1±4.6)d、(6.2±1.4)d]均明显短于对照组[(10.4±7.0)d、(11.0±4.0)d、(8.4±1.3)d](P<0.05);治疗组的显效率(39%)和总有效率(90%)均明显高于对照组(34%、78%)(P<0.05);治疗组的复发率(10%)低于对照组(24%)(P<0.05);两组不良反应比较差异无统计学意义(P>0.05).结论:顺尔宁治疗小儿哮喘的临床疗效优于传统治疗,值得推广应用.%Objective: To evaluate of clinical efficacy Singulair in treatment of children with asthma. Methods: 100 cases rnof children with asthma treated in our hospital from May 2009 to June 2010 were randomly divided into control group and rntreatment group, each group 50 cases, control group was treated with β2-agonist and bronchodilator, other conventional rntreatment; treatment group was given conventional treatment plus Singulair. The treatment lasted for 3 months, followed up rnfor 6 months. Before and after treatment changes in blood gas and forced expiratory volume in 1 second (FEV1) were obrnserved; observed symptoms disappearance time, the incidence of adverse reactions and the recurrence rate; evaluated clinirncal efficacy. Results: After treatment, the treatment group, PaO2 (75.l±6.7) mm Hg and PaCO2 (33.5±5.1) mm Hg were rnhigher than those of the control group [(70.0±6.2) mm Hg, (39.9±5.6) mm Hg] (P＜0.05); treatment group FEV1 (90±18) ％rnwas significantly higher than control group with (82±15)％ (P＜0.05); treatment group coughing, shortness of breath and rnwheezing and other symptoms disappeared time [(7.6±4.2) d, (8.1±4.6) d, (6.2±1.4) d] were significantly shorter in the conrntrol group [(10.4±7.0) d, (11.0±4.0) d, (8.4±1.3) d] (P＜0.05); the treatment group effective (39％) and total effective rate rn(90％) were significantly higher control group (34％,78％) (P＜0.05); the treatment group, relapse rate (10％) was lower than rnthe control group (24％) (P＜0.05); adverse reactions difference between the two groups was not significant (P＞0.05). Conrnclusion: Clinical efficacy of Singulair in treatment of children with asthma is superior to conventional therapy, should be rnwidely applied.
展开▼
